Breviscapine alleviates myocardial ischemia-reperfusion injury in diabetes ratsPurpose: To investigate the protective effect of breviscapine on myocardial ischemia-reperfusion injury (MIRI) in diabetes rats.
Methods: Forty rats were divided into control, diabetes, MIRI of diabetes, and treatment groups. The MIRI of diabetes model was established in the latter two groups. Then, the treatment group was treated with 100 mg/kg breviscapine by intraperitoneal injection for 14 consecutive days.
Results: After treatment, compared with MIRI of diabetes group, in treatment group the serum fasting blood glucose, fasting insulin, homeostasis model assessment of insulin resistance, and glycosylated hemoglobin levels decreased, the serum total cholesterol, triacylglycerol, and low-density lipoprotein cholesterol levels decreased, the serum high-density lipoprotein cholesterol level increased, the heart rate decreased, the mean arterial pressure, left ventricular ejection fraction, and fractional shortening increased, the serum cardiac troponin I, and creatine kinase-MB levels decreased, the myocardial tumor necrosis factor α and interleukin-6 levels decreased, the myocardial superoxide dismutase level increased, and the myocardial malondialdehyde level decreased (all P < 0.05).
Conclusions: For treating MIRI of diabetes in rats, the breviscapine can reduce the blood glucose and lipid levels, improve the cardiac function, reduce the myocardial injury, and decrease the inflammatory response and oxidative stress, thus exerting the alleviating effect.
Key words
Myocardial; Ischemia-Reperfusion Injury; Diabetes Mellitus; Inflammatory Response; Oxidative Stress
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Source: Elaborated by the authors. aP < 0.05 vs. group 1; bP < 0.05 vs. group 2; cP < 0.05 vs. group 3; group 1: control; group 2: diabetes; group 3: myocardial ischemia-reperfusion injury of diabetes; group 4: treatment; FBG: fasting blood glucose; FINS: fasting insulin; HOMA-IR: homeostasis model assessment of insulin resistance; HbA1c: glycosylated hemoglobin.
Source: Elaborated by the authors. aP < 0.05 vs. group 1; bP < 0.05 vs. group 2; cP < 0.05 vs. group 3; group 1: control; group 2: diabetes; group 3: myocardial ischemia-reperfusion injury of diabetes; group 4: treatment; TC: total cholesterol; TG: triacylglycerol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol.
Source: Elaborated by the authors. aP < 0.05 vs. group 1; bP < 0.05 vs. group 2; cP < 0.05 vs. group 3; group 1: control; group 2: diabetes; group 3: myocardial ischemia-reperfusion injury of diabetes; group 4: treatment; HR: hear rate; MAP: mean arterial pressure; LVEF: left ventricular ejection fraction; FS: fractional shortening.
Source: Elaborated by the authors. aP < 0.05 vs. group 1; bP < 0.05 vs. group 2; cP < 0.05 vs. group 3; group 1: control; group 2: diabetes; group 3: myocardial ischemia-reperfusion injury of diabetes; group 4: treatment; cTnI: cardiac troponin I; CK-MB: creatine kinase-MB.
Source: Elaborated by the authors. aP < 0.05 vs. group 1; bP < 0.05 vs. group 2; cP < 0.05 vs. group 3; group 1: control; group 2: diabetes; group 3: myocardial ischemia-reperfusion injury of diabetes; group 4: treatment; TNF-α: tumor necrosis factor α; IL-6: interleukin-6.
Source: Elaborated by the authors. aP < 0.05 vs. group 1; bP < 0.05 vs. group 2; cP < 0.05 vs. group 3; group 1: control; group 2: diabetes; group 3: myocardial ischemia-reperfusion injury of diabetes; group 4: treatment; SOD: superoxide dismutase; MDA: malondialdehyde.